Search results
Results from the WOW.Com Content Network
Evolocumab, [6] sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) .
Orlistat (also known by trade names Xenical and Alli) is a diet pill that works by blocking the enzymes that digest fat. As a result, some fat cannot be absorbed from the gut and is excreted in the feces instead of being metabolically digested and absorbed, sometimes causing oily anal leakage.
Neurogenic bowel dysfunction (NBD) is reduced ability or inability to control defecation due to deterioration of or injury to the nervous system, resulting in fecal incontinence or constipation. [1] It is common in people with spinal cord injury (SCI), multiple sclerosis (MS) or spina bifida .
Bile acid malabsorption (BAM), known also as bile acid diarrhea, is a cause of several gut-related problems, the main one being chronic diarrhea.It has also been called bile acid-induced diarrhea, cholerheic or choleretic enteropathy, bile salt diarrhea or bile salt malabsorption.
If you're regularly waking up bloated and backed up, try this GI expert-approved morning routine to encourage a bowel movement and overall better gut health. This is the best morning routine to ...
Health therapist Sara Reardon discusses the mistakes people make when it comes to their pelvic floor. (Photo illustration: Blake Cale for Yahoo News; photos: Sara Reardon, Getty Images) (Photo ...
Food and diet The types of food consumed and diet consumed plays a role in the manifestation of FGID [ 27 ] and also their relationship to intestinal microbiota. [ 28 ] Studies have shown that specific changes in diet (e.g., low FODMAP—fermentable oligo-, di-, and monosaccharides and polyols, or gluten restriction in some patients) may help ...
The latest approval comes after a setback in April, when The U.S. Food and Drug Administration (FDA) had declined clearance citing issues related to the proposed manufacturing of the treatment.